EpiCast Report: Hyperparathyroidism – Epidemiology Forecast to 2025

HPT is a disorder of the parathyroid gland that is caused due to presence of excessive parathyroid hormone (PTH) in the bloodstream. An increase in the activity of parathyroid glands, due to intrinsic abnormal changes, causes alteration of the excretion of PTH, and is known as PHPT. However, an extrinsic abnormal change affecting calcium homoeostasis, which stimulates production of PTH, is known as SHPT. In THPT, a state of autonomous secretion of PTH usually occurs as a result of longstanding CKD.

To forecast the diagnosed prevalent cases of PHPT, total prevalent cases for SHPT, and diagnosed prevalent cases of THPT in the 7MM, GlobalData epidemiologists conducted a thorough literature review to find country-specific sources that provided data for the above-mentioned segmentations of the general population in the 7MM. In order to improve the accuracy of the forecast diagnosed prevalent cases of PHPT, total prevalent cases for SHPT, and diagnosed prevalent cases of THPT, GlobalData epidemiologists used studies that provided data based on uniform diagnostic criteria and disease definition for these parameters across the 7MM.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of PHPT will increase from 2,055,167 cases in 2015 to 2,373,547 cases in 2025, at an Annual Growth Rate (AGR) of 1.55%. The US will have the highest number of cases of PHPT among the 7MM throughout the forecast period, while Japan will have the lowest. In the 7MM, GlobalData epidemiologists forecast that the total prevalent cases of SHPT will increase from 75,326,251 cases in 2015 to 85,592,876 cases in 2025, at an AGR of 1.36%.

Scope

The Hyperparathyroidism (HPT) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of HPT in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of primary HPT (PHPT), total prevalent cases for secondary HPT (SHPT) (including diagnosed and undiagnosed), and diagnosed prevalent cases of tertiary HPT (THPT), based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of PHPT and total prevalent cases of SHPT are further segmented by sex and age (ages 20 years and above), and the diagnosed prevalent cases of THPT are segmented by sex. GlobalData epidemiologists also provide prevalent cases of SHPT in the total chronic kidney disease (CKD) pre-dialysis prevalent population and also in the total CKD dialysis prevalent population in the 7MM for the forecast period.

The hyperparathyroidism epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2 ...

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 Prevalence

2.4 Forecast Methodology

2.4.1 Sources Used

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast of HPT (2015–2025)

2.5.1 Diagnosed Prevalent Cases

2.5.2 Total Prevalent Cases of SHPT

2.5.3 Diagnosed Prevalent Cases of THPT

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologists

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.3 About GlobalData

3.4 About EpiCast

3.5 Disclaimer

List of Tables

1.1 List of Tables

Table 1: Risk Factors and Comorbidities of HPT

Table 2: Diagnositc Criteria for PHPT, SHPT, and THPT

Table 3: 7MM ...

1.1 List of Tables

Table 1: Risk Factors and Comorbidities of HPT

Table 2: Diagnositc Criteria for PHPT, SHPT, and THPT

Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PHPT

Table 4: 7MM, Sources Used to Forecast the Total Prevalent Cases of SHPT

Table 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of THPT

Table 6: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD

Table 7: 7MM, Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, Both Sexes, N (Row %), 2015

Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years N (Row %), 2015

Table 10: 7MM Total Prevalent Cases of SHPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Table 11: 7MM, Age-Specific Total Prevalent Cases of SHPT, Both Sexes, N (Row %), 2015

Table 12: 7MM, Sex-Specific Total Prevalent Cases of SHPT, Ages ≥20 Years, N (Row %), 2015

Table 13: 7MM, SHPT in Pre-Dialysis CKD Total Prevalent Population (Stages 3–5), Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Table 14: 7MM, SHPT in Dialysis CKD Total Prevalent Population (Stage 5D), Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Table 15: 7MM, Diagnosed Prevalent Cases of THPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Table 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of THPT, Ages ≥20 Years, N (Row %), 2015

List of Figures

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Figure 2 ...

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, Both Sexes, N, 2015

Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, 2015

Figure 4: 7MM, Age-Standardized Diagnosed Prevalent Cases of PHPT, Ages ≥20 Years, N, 2015

Figure 5: 7MM, Total Prevalent Cases of SHPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Figure 6: 7MM, Age-Specific Total Prevalence of SHPT, Ages ≥20 Years, Both Sexes, N, 2015

Figure 7: 7MM, Sex-Specific Total Prevalent Cases of SHPT, Ages ≥20 Years, N, 2015

Figure 8: 7MM, Age-Standardized Total Prevalent Cases of SHPT, Ages ≥20 Years, N, 2015

Figure 9: 7MM, SHPT in Pre-Dialysis CKD Total Prevalent Population (Stages 3–5), Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Figure 10: 7MM, SHPT in Dialysis CKD Total Prevalent Population (Stages 5D), Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Figure 11: 7MM, Diagnosed Prevalent Cases of THPT, Ages ≥20 Years, Both Sexes, N, Selected Years 2015–2025

Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of THPT, Ages ≥20 Years, N, 2015

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports